Key Drivers
- Cash cushion
- Operating losses
- Rich valuation
AIAI Summary
MESO has shifted from a purely speculative biotech story to a real commercial ramp thanks to Ryoncil, but the investment now depends on whether payer coverage, repeat center use, and revenue growth can scale fast enough to offset persistent losses, dilution risk, and a still-rich valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash cushion
- •Operating losses
- •Rich valuation
MESO has solid cash and gross margins, but severe operating losses, weakening liquidity, high intangible asset exposure, and an extremely rich valuation make the stock fundamentally risky.
Price Behavior
Key Price Behavior Insights:
- •Support bounce
- •Rejection zone
- •Volatile swings
MESO remains in a downtrend over the last month, but a bounce off $14.44–$14.51 suggests short-term support, while the trend stays weak until it reclaims $15.81–$16.00.
Sharp swing from $16.61 on 2026-04-20 to $14.44 on 2026-05-12 signals elevated volatility
Sentiment & News
Key News Insights:
- •Revenue growth
- •Cash efficiency
- •Trial milestone
Mesoblast reported strong Ryoncil® quarterly revenue, improved cash discipline, and a key Phase 3 recruitment milestone for rexlemestrocel-L, signaling progress across both commercialization and late-stage pipeline development.
This update is modestly positive for the instrument as it shows both nearer-term commercial traction and continued advancement of a potentially valuable late-stage asset
Similar Companies in Healthcare
Other companies in the same sector with AI ratings